<DOC>
	<DOCNO>NCT01576731</DOCNO>
	<brief_summary>As measure secondary prophylaxis , final objective avoid infection , suggest use antiretroviral therapy . This know post-exposure prophylaxis ( PEP ) . Although different recommendation , almost every guideline recommend use 3 drug PEP USA Europe . Toxicity one main limitation PEP . Side effect PEP usual , attribute mainly PI main reason poor adherence lose follow-up . A current standard regimen AZT+3TC ( Combivir® ) tenofovir+emtricitabine ( Truvada® ) plus PI lopinavir/r . Toxicity associate regimen high ( 31-85 % case ) , high tolerability , integrase inhibitor ( raltegravir ) could adequate drug PEP .</brief_summary>
	<brief_title>Study Comparing Two Alternatives Antiretroviral Therapy Post-exposure Prophylaxis HIV-1 : Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir ( RAL-PEP )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Potentially sexual exposition HIV Pregnancy Source case antiretroviral resistance treatment contraindicate drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV Infection</keyword>
	<keyword>Postexposure prophylaxis</keyword>
</DOC>